Submit Animal Toxicity Data: CDSCO panel Tells Dr. Reddy's on Ferric carboxymaltose injection

Published On 2023-05-14 12:30 GMT   |   Update On 2023-05-14 12:30 GMT

New Delhi: In response to the drug major Dr. Reddy's Laboratories' proposal to manufacture and market the Ferric Carboxymaltose Injection, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has opined that the firm should submit animal toxicity data as per New Drugs and Clinical Trial Rules 2019.

This came after the firm presented the proposal for manufacturing and marketing of Ferric Carboxymaltose Injection 50 mg/ml in fill volumes 100mg/2mL, 500mg/10mL, 750mg/15mL, and 1000mg/20mL vials (Ferric Carboxymaltose Injection 50mg/mL in 2mL vial, 10mL vial, 15mL vial, and 20 mL vial) as an additional pack sizes indicated “for the treatment of iron deficiency in adults when oral iron preparations are ineffective or cannot be used”.

Ferric carboxymaltose injection is in a class of medications called iron replacement products. Ferric carboxymaltose injection is used to treat iron-deficiency anemia (a lower-than-normal number of red blood cells due to too little iron) in adults who cannot tolerate or who could not successfully be treated with iron supplements taken by mouth.

Ferric carboxymaltose injection is in a class of medications called iron replacement products. It works by replenishing iron stores so that the body can make more red blood cells.

At the recent SEC meeting for Oncology and Hematology held on the 27th of April 2023, the expert panel reviewed the proposal for manufacturing and marketing of Ferric Carboxymaltose Injection 50 mg/ml in fill volumes 100mg/2mL, 500mg/10mL, 750mg/15mL and 1000mg/20mL vials (Ferric Carboxymaltose Injection 50mg/mL in 2mL vial, 10mL vial, 15mL vial, and 20 mL vial) as an additional pack sizes indicated “for the treatment of iron deficiency in adults when oral iron preparations are ineffective or cannot be used”.

The committee also noted that the firm also presented the comparative pharmaceutical data with reference products along with justification for the bioequivalence (BE) study and clinical study waiver.
After detailed deliberation, the committee recommended that the firm should submit animal toxicity data as per New Drugs and Clinical Trial Rules 2019 for review by the committee for further consideration of the BE study and clinical study waiver.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News